dc.description.abstract | It’s known that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins for short, are widely used for the treatment of hypercholesterolemia and have demonstrated efficacy for primary and secondary prevention of coronary heart disease (CHD). They are safe and usually well tolerated. The most frequently reported adverse events, including gastrointestinal disturbances, liver enzyme elevation, and muscle pain/weakness, are usually mild and there is almost no need to interrupt the therapy. Nevertheless, rhabdomyolysis is a quite severe adverse effect, though rare, and is related to the dosage of statins. Furthermore, statins are metabolized mainly by CYP system. The risk of rhabdomyolysis will be increased by drugs that share the same metabolic pathway.
In this thesis, the prescribing patterns of statins and statin-drug interactions in outpatient are analyzed through the National Health Insurance Research Database in Taiwan. The relative risk of rhabdomyolysis and the incidence rate of mild muscular side effects are also examined.
All cohort datasets within year 2002, total 200,000 patients, are included. The statin-drug interactions are analyzed not only on the same prescription but among different prescriptions of a person. The prescribing patterns are expressed in terms of person-time, cumulative using days per year, prescribed daily doses (PDD), the prevalence of potentially severe statin-drug interactions, and the duration of combination use. Using persons not taking statins as a control, a case-control study was performed to exam the relative risk of rhabdomyolysis in patients on statins. As for the incidence rates of mild muscular side effects, five different groups are selected and compared with each other. The rates are calculated by using case numbers as the numerator and time interval of drug used as the denominator.
The study shows that atorvastatin was the most frequently prescribed statin. The average cumulative using days per year of statins are about 120 days. The prevalence of statin-drug interactions is 18.5 %, and 60 % of the total interactions are prescribed by the same doctors. Diltiazem and gemfibrozil were the two most frequently prescribed drugs that combined with statins, and cyclosporine is the drug that has the longest duration of combination. PDDs of statins in combination was not significant different from those in single use. Patients on statin therapy are much older than the general population and have higher incidence of underlying circulatory and endocrine diseases (p < 0.05).
In this study, no of rhabdomyolysis was detected in statin users. After controlling the predisposing factors such as age, gender, duration for exposing to drug, DM and hypothyroidism, the incidence of mild muscular side effects for statin users was 1.6 times (95 % CI 1.3, 1.9; p < 0.0001) of those not using statins, and the odds ratio in fibrate users was even higher (OR 2.7; 95 % CI 1.9, 3.8; p < 0.0001).
Drug-drug interactions easily occur for drugs metabolized via CYP3A isoenzyme under polypharmacy. Atorvastatin and simvastatin that are metabolized by CYP3A, are the two most frequently prescribed statins in our research. Around 40 % of interactions are difficult to detect due to patients’ habits of doctor shopping. Although there is no rhabdomyolysis was detected in our study in patients using statins, statin’s monotherapy increased the risk of muscular side effects. It is important to monitor the use of statins and provide proper patient education.
Small sample size and short duration to follow up are the limitations of this study. That National Health Research Institutes (NHRI) set a new database of patients on lipid lowering drugs and further longitudinal studies on the use of statins are recommended. | en |
dc.relation.reference | 1. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13
2. Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf 2000;23:197-213
3. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41:343-70
4. Cottrell DA, Marshall BJ, Falko JM. Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. Curr Opin Cardiol 2003;18:301-8
5. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003;163:553-64
6. De Angelis G. The influence of statin characteristics on their safety and tolerability. Int J Clin Pract 2004;58:945-55
7. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90
8. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2004;19:117-25
9. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7
10. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22
11. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
12. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9
13. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57
14. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
15. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30
16. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007
17. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58
18. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
19. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
20. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
21. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
22. Muscari A, Puddu GM, Puddu P. Lipid-lowering drugs: are adverse effects predictable and reversible? Cardiology 2002;97:115-21
23. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001;35:908-17
24. Maritz FJ. Efficacy and dangers of statin therapy. Cardiovasc J S Afr 2002;13:200-3
25. Pasternak RC, Smith SC, Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-72
26. Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004;116:408-16
27. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109(23 Suppl 1):III50-7
28. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett 2002;128:159-68
29. Wortmann RL. Lipid-lowering agents and myopathy. Curr Opin Rheumatol 2002;14:643-7
30. Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J 2004;147:956-65
31. Flint OP, Masters BA, Gregg RE, Durham SK. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol 1997;145:91-8
32. Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993;33:226-9
33. Guijarro C, Blanco-Colio LM, Ortego M, et al. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998;83:490-500
34. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35:1096-107
35. Drug facts and comparisons. 59th ed. St. Louis: Facts and Comparisons; 2005.
36. Jankel CA, Speedie SM. Detecting drug interactions: a review of the literature. DICP 1990;24:982-9
37. Herman RJ. Drug interactions and the statins. CMAJ 1999;161:1281-6
38. Martin J, Krum H. Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant? Drug Saf 2003;26:13-21
39. Bolego C, Baetta R, Bellosta S, Corsini A, Paoletti R. Safety considerations for statins. Curr Opin Lipidol 2002;13:637-44
40. Gibbs MA, Hosea NA. Factors affecting the clinical development of cytochrome p450 3A substrates. Clin Pharmacokinet 2003;42:969-84
41. Bottorff M. 'Fire and forget?' - pharmacological considerations in coronary care. Atherosclerosis 1999;147 (Suppl 1):S23-30
42. Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atheroscler Suppl 2002;3:35-40
43. Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000;68:122-9
44. Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002;30:1280-7
45. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002;301:1042-51
46. Prueksaritanont T, Subramanian R, Fang X, et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002;30:505-12
47. Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004;13:417-26
48. Bermingham RP, Whitsitt TB, Smart ML, Nowak DP, Scalley RD. Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil. Am J Health Syst Pharm 2000;57:461-4
49. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002;346:539-40
50. Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001;12:565-9
51. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90
52. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002;36:288-95
53. Tatro DS. Drug interaction facts : the authority on drug interactions. 2005 ed. St. Louis, Mo.: Facts and Comparisons; 2005.
54. Klasco RK (Ed): DRUGDEX System. Thomson Micromedex, Greenwood Village, Colorado (Vol. 124 expires 6/2005).
55. Stockley IH. Stockley's drug interactions : a source book of interactions, their mechanisms, clinical importance and management. 6th ed. London: Pharmaceutical Press; 2002.
56. Griffin JP. A manual of adverse drug interactions. 5th ed. Amsterdam: Elsevier; 1997.
57. Hansten PD. Hansten and Horn's managing clinically important drug interactions. Vancouver: WA : Applied Therapeutics; 1998.
58. Klasco RK (Ed): DRUG-REAX System. Thomson Micromedex, Greenwood Village, Colorado (Vol. 124 expires 6/2005).
59. Jamil S, Iqbal P. Rhabdomyolysis induced by a single dose of a statin. Heart. Jan 2004;90(1):e3.
60. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol. Jul 1998;46(1):49-53.
61. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63:332-41
62. Kantola T, Backman JT, Niemi M, Kivisto KT, Neuvonen PJ. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000;56:225-9
63. Floyd JA. Systematic sampling: theory and clinical methods. Nurs Res 1993;42:290-3
64. Chen TJ, Lin SJ, Chen LK, Hwang SJ, Chou LF. Prevalence of antilipemic drug use in Taiwan: analysis of a sampling cohort within the national health insurance. J Chin Med Assoc 2003;66:39-45
65. Ratz Bravo AE, Tchambaz L, Krahenbuhl-Melcher A, Hess L, Schlienger RG, Krahenbuhl S. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf 2005;28:263-75
66. Fellstrom B. Impact and management of hyperlipidemia posttransplantation. Transplantation 2000;70(11 Suppl):SS51-7
67. Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant 2001;16:1545-9
68. Southworth MR, Mauro VF. The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients. Ann Pharmacother 1997;31:489-91
69. Asberg A. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs 2003;63:367-78
70. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002;25:1198-202
71. Hansten PD. Possible risks to patients receiving statins combined with other medications. J Am Coll Cardiol 2003;41:519-20
72. Ellen RL, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 1998;81(4A):60B-65B
73. Davidson MH, Toth PP. Combination therapy in the management of complex dyslipidemias. Curr Opin Lipidol 2004;15:423-31
74. Atorvastatin (Lipitor). Pfizer. Physicians' Desk Reference (electronic version), Thomson Micromedex, Greenwood Village, Colorado (Vol. 124 expires 6/2005).
75. Pravastatin (Pravachol), Bristol Myers Squibb. Physicians' Desk Reference (electronic version), Thomson Micromedex, Greenwood Village, Colorado (Vol. 124 expires 6/2005 ).
76. Fluvastatin (Lescol). Novartis. Physicians' Desk Reference (electronic version), Thomson Micromedex, Greenwood Village, Colorado (Vol. 124 expires 6/2005).
77. Lovastatin (Mevacor). Merck. Physicians' Desk Reference (electronic version), Thomson Micromedex, Greenwood Village, Colorado (Vol. 124 expires 6/2005).
78. Simvastatin (Zocor). Merck. Physicians' Desk Reference (electronic version), Thomson Micromedex, Greenwood Village, Colorado (Vol. 124 expires 6/2005).
79. Physicians' Desk Reference (electronic version), Thomson Micromedex, Greenwood Village, Colorado (Vol. 124 expires 6/2005).
80. Sniderman AD. Is there value in liver function test and creatine phosphokinase monitoring with statin use? Am J Cardiol 2004;94(9A):30F-34F
81. Di Martino M, Degli Esposti L, Ruffo P, et al. Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy. Eur J Clin Pharmacol 2005;61:225-30 | en |